CA
NZ
UK
AU
IND
US
Obsidian develops engineered tumor-infiltrating lymphocyte cell therapies for solid tumors. Its lead candidate, OBX-115, is in a Phase 2 study in advanced melanoma and a Phase 1 study in non-small cell lung cancer. The merger with Galera Therapeutics closed in early August 2026 alongside …
Policy support played a large part. The company recognized USD 12.7 million of Section 45Z production tax credits in cost of sales, plus USD 9.2 million withinEquitymethod income. It closed a USD 30.7 million sale of federal tax credits, including a USD 26.0 million …
The most recent verified corporate action is a one-for-ten reverse split of the American depositary shares, effective May 26, 2026. The Class A shares themselves were unchanged, but each depositary share now represents 2,500 of them instead of 250, so any price history before …
Revenue of USD 18.4 million missed the company's own projections, which it attributed to project timing. The net loss widened to USD 6.7 million, or USD 0.05 a share, from USD 0.3 million, although the year-earlier quarter included an USD 11.7 million non-cashFair Valuegain. …
The company supplies subsystems for missile, hypersonic, space and maritime defense programs. Tactical Missiles and Integrated Defense Systems revenue rose 51.9% to USD 67.6 million, and Hypersonics and Strategic Missile Defense rose 39.6% to USD 51.1 million. Maritime Defense Systems, a new reporting line, …
The company builds launch vehicles, lunar landers and, since its SciTec acquisition, national security software and systems. Its second-quarter 2026 report, released August 11, 2026, showed revenue of USD 117.7 million, up 45.5% on the prior quarter, against USD 15.5 million a year earlier. …
Profitability improved on an adjusted basis. GAAP grossMarginwas 33.1% against 31.1%, and non-GAAP gross margin was 34.7%. Adjusted EBITDA of USD 11.1 million compared with USD 7.1 million a year ago, and non-GAAPNet Incomewas USD 10.2 million. On a GAAP basis the company still …
The most recent dated item found was a published report on November 5, 2026 saying net profit for the six months ended June 30, 2026 fell about 70% from a year earlier, to RMB 19.78 million. Earlier, on August 15, 2026, the company was …
The three-figure quote is largely a product of a reverse split, not of a re-rating. Shareholders approved consolidation authority at an extraordinary meeting on April 6, 2026, and the board set a 25-for-1 ratio on May 25, 2026. The company announced it on June …
Key HighlightsChanson International Holding (NASDAQ:CHSN) was trading up 25.53% at USD 2.95 on Friday, November 6, 2026, on the screener, and no company announcement dated that week explaining the move was found.A 100-for-1 share consolidation took effect on May 7, 2026, cutting Class A …
Please wait processing your request...